Tyrosinase is a multifunctional copper-containing oxidase enzyme that initiates melanin synthesis in humans. Excessive accumulation of melanin pigments or the overexpression of tyrosinase may result in skin-related disorders such as aging spots, wrinkles, melasma, freckles, lentigo, ephelides, nevus, browning and melanoma. Nature expresses itself through the plants as a source of phytochemicals with diverse biological properties. Among these bioactive compounds, flavonoids represent a huge natural class with different categories such as flavones, flavonols, isoflavones, flavan-3-ols, flavanones and chalcones that display antioxidant and tyrosinase inhibitor activities with a diversity of mechanistic approaches. In this review, we explore the role of novel or known flavonoids isolated from different plant species and their participation as tyrosinase inhibitors reported in the last five years from 2016 to 2021. We also discuss the mechanistic approaches through the different studies carried out on these compounds, including in vitro, in vivo and in silico computational research. Information was obtained from Google Scholar, PubMed, and Science Direct. We hope that the updated comprehensive data presented in this review will help researchers to develop new safe, efficacious, and effective drug or skin care products for the prevention of and/or protection against skin-aging disorders.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705159 | PMC |
http://dx.doi.org/10.3390/molecules26247546 | DOI Listing |
Alzheimers Dement
December 2024
Department of Radiology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Background: Hippocampal atrophy is an established biomarker of neurodegeneration in Alzheimer's disease, affecting specific subfields (De Flores, La Joie and Chételat, 2015). In this study, we used 7T MRI and advanced diffusion MRI (dMRI) to investigate the relationship between hippocampal subfield volumes and microstructure and assess their sensitivity to cognitive impairment.
Method: Seventeen cognitively impaired (CI; age: 69±8, M/F: 12/5, MMSE: 28) and 22 cognitively unimpaired subjects (CU; age: 62±10, M/F: 6/16) were recruited in the context of the COSCODE project (Ribaldi et al.
Alzheimers Dement
December 2024
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Background: Astrocyte reactivity marked by elevations in Glial Fibrillary Acidic Protein(GFAP), was found to increase Phosphorylated Tau181(pTau181) induced neurodegenerative effects in Alzheimer's Disease (Bellaver et al., 2023). Nevertheless, the effect of the GFAP- pTau181 axis in vascular/mixed dementias has yet to be completely elucidated.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, NA, Taiwan.
Background: Metabolic syndrome (MS) has been linked to cognitive functions, yet limited research has explored the longitudinal effects of changes in MS on cognitive performance. This study aims to investigate the predictive impact of longitudinal MS status on cognitive performance and dissect its sex-specific influence over a 10-year follow-up.
Method: In this community-based prospective cohort study, 766 healthy subjects underwent baseline MS status assessment between 2006 and 2011.
Background: Timely identification of mild cognitive impairment (MCI) is key to early intervention. While primary care providers are the most likely entry point to detect early signs of MCI, their detection rates are low. Building upon a published study, we used electronic health records (EHR) to develop a clinically enhanced MCI risk prediction algorithm.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Centre for Healthy Brain Ageing (CHeBA), University of New South Wales, UNSW Sydney, NSW, Australia.
Background: The Maintain Your Brain (MYB) randomised controlled trial (RCT) aimed to prevent cognitive decline and dementia through a multidomain risk-reduction intervention delivered digitally. The intervention targeted four modifiable risk areas (physical inactivity, poor diet, cognitive inactivity, and depression and/or anxiety). MYB ran for three years and targeted older Australians aged 55-77 years.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!